For biotech founders · Kobe Biomedical Innovation Cluster
Summit I · 17–18 Oct · Summit II · 24–25 Oct · Finale · 26 Oct 2026
The only developed country where you can fast-track to market in as little as six months, channel that data into FDA and EMA approval years earlier, and where private companies can shape custom regulation through special zones.
With support of
Mirai Tech City is connecting US, EU and Japanese companies, scientists, investors and legislators to accelerate frontier biotech.
Cell and gene therapy, AI-designed drugs, N-of-1 medicine, brain-computer interfaces. Trillions of dollars, and the definition of human biology itself.
Under the Act on the Safety of Regenerative Medicine, a cell or gene therapy can be sold on a self-pay basis once it has Phase 1 safety data — six to twelve months. Conditional Early Approval does the same nationally for small molecules, biologics and devices, around four years ahead of the FDA.
Nobel-winning researchers at Kyoto and Osaka, RIKEN's labs, purpose-built clinical clusters, and iPS cells — the field Japan invented, whose first therapies reached market here in 2026. Every patient is followed for life in one national database, and the FDA and EMA accept the data.
Sandboxes, ten National Strategic Special Zones and two Super Cities, where regulation can be proposed by private entities, tested in the open, then spread nationally once proven.
Third largest pharmaceutical market and third largest R&D spender on earth: $146 billion a year (¥23.8 trillion), 3.7% of GDP, with biotech R&D up 32% last year. AMED matches registered venture capital two to one in non-dilutive grants. National insurance pays 70 to 90%, with a monthly cap on what any patient pays.
The machinery exists, the government has the votes, and the data finally travels.
The LDP won a two-thirds supermajority in February 2026. Two-thirds of the drugs approved in the US and Europe over the past decade never began development in Japan, and the population is old and getting older. The government knows both. Biotech and startups now sit among seventeen strategic sectors — and this government has the votes to act.
ICH E6(R3) became the global standard for clinical data in 2025. Annex 2, covering real-world data and pragmatic designs, was adopted in June 2026 and takes effect in Europe in January 2027. Data generated in Japan to that standard can be used directly in FDA and EMA filings.
GLP-1s proved a new category can reach tens of millions in a few years. When approval lags demand, patients buy compounded copies or fly to clinics with no oversight. Japan's answer is safety first, then commercialization on the way to efficacy.
A therapy built for one patient's mutation cannot run a thousand-patient trial; there is only one patient. No brain implant for paralysis holds full market approval anywhere, because the standards for judging one are still being written. Japan already has the machinery for writing them — sandboxes, special zones, and conditional approval that covers devices.
For biotech startups preparing for clinical trials, or post Phase 1b, aiming to reach patients 10× faster at a fraction of the cost
i
The first three go to market via the Act on the Safety of Regenerative Medicine. The rest via Conditional Early Approval.
ii
No brain implant for paralysis holds full market approval anywhere, because the standards for judging one are still being written. Japan's conditional approval route covers devices.
iii
A therapy built for one patient's mutation cannot run a thousand-patient trial. Every patient in Japan is followed for life in one national database, to a standard the FDA and EMA accept.
Leave with a go-to-market plan measured in months, not years. Built against the Act on the Safety of Regenerative Medicine and the Conditional Early Approval route, with the people who have taken products through both.
Access the capital and the partners already active in the Japanese ecosystem — AMED-registered funds, the institutions on Port Island, and the licensing partners who can carry a therapy into this market.
Japan is the one place where private entities can propose regulation: sandboxes, ten National Strategic Special Zones and two Super Cities, where a rule can be tested locally and then spread nationally once proven. Sit in the drafting sessions and help write the framework frontier biotech is still missing.
The package, and what the same things cost if you buy them separately.
Launch price. $4,000 after.
And the last line is the one you cannot actually buy. A consultancy writes recommendations on your behalf. It does not put a founder in the room where scientists from the West and their Japanese peers compile, together, what frontier work needs to thrive in Japan — and shape it into the kind of proposal the Special Zone framework was created to receive. That part is not for sale anywhere — it is what this October is.
Both summit weekends, the week between them, and a room in Sannomiya for the whole run. Kobe, Japan.
